In late 2011, Yale University combined 2 successful exisiting cores, Small Molecule Discovery Center and High Throughput Cell Biology, into a single core: Yale Center for Molecular Discovery (YCMD). YCMD was established to provide high-throughput and high-content screening and assay development, as well as medicinal chemistry services. YCMD works with individuals from Yale Cancer Center (YCC) and other Yale laboratories to design, optimize, and execute all phases of small molecule and siRNA screening in customized biochemical, cell-based, and model organism-based assays. YCMD synergizes existing technologies and expertise and helps expand the capabilities and impact of investigators? novel concepts by mining pathways or identifying small molecule leads in a cost-effective manner. As a YCC shared resource, YCMD offers services that span a range of investigator-driven goals and needs. During the most recent funding period, 49 laboratories have used YCMD. Thirty of these users (61%) were YCC members. This Shared Resource was most widely used by Developmental Therapeutics (DT), but nearly all of the YCC research programs benefited from this core. YCMD helped YCC members in basic and translational research address fundamental questions in biology. In pursuit of translational research, YCMD scientists discover novel small molecule probes that may serve as starting points for new therapeutics, to understand basic biological processes and to crystallize proteins in unique conformations that reveal their mechanisms of action. Crystal structures enable structure-based drug design to inform hypotheses for development of new molecules with increased binding, solubility, or attachment of linker groups.
The Specific Aims of YCMD are to: (1) Facilitate new lines of research for YCC members and other Yale faculty; (2) Support early-stage development for translational research programs; and (3) Make the YCMD suite of technologies required for assay development and high-throughput screening accessible to a wide user base.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA016359-41
Application #
9989593
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
Project End
Budget Start
2020-08-01
Budget End
2021-07-31
Support Year
41
Fiscal Year
2020
Total Cost
Indirect Cost
Name
Yale University
Department
Type
DUNS #
043207562
City
New Haven
State
CT
Country
United States
Zip Code
06520
Chen, Ling; Azuma, Takeshi; Yu, Weiwei et al. (2018) B7-H1 maintains the polyclonal T cell response by protecting dendritic cells from cytotoxic T lymphocyte destruction. Proc Natl Acad Sci U S A 115:3126-3131
Zhang, Jinhua; Song, Kun; Wang, Jun et al. (2018) S100A4 blockage alleviates agonistic anti-CD137 antibody-induced liver pathology without disruption of antitumor immunity. Oncoimmunology 7:e1296996
Kelada, Olivia J; Decker, Roy H; Nath, Sameer K et al. (2018) High Single Doses of Radiation May Induce Elevated Levels of Hypoxia in Early-Stage Non-Small Cell Lung Cancer Tumors. Int J Radiat Oncol Biol Phys 102:174-183
Powles, Ryan L; Redmond, David; Sotiriou, Christos et al. (2018) Association of T-Cell Receptor Repertoire Use With Response to Combined Trastuzumab-Lapatinib Treatment of HER2-Positive Breast Cancer: Secondary Analysis of the NeoALTTO Randomized Clinical Trial. JAMA Oncol 4:e181564
Wang, Shi-Yi; Hsu, Sylvia H; Huang, Siwan et al. (2018) Regional Practice Patterns and Racial/Ethnic Differences in Intensity of End-of-Life Care. Health Serv Res 53:4291-4309
Gettinger, S N; Choi, J; Mani, N et al. (2018) A dormant TIL phenotype defines non-small cell lung carcinomas sensitive to immune checkpoint blockers. Nat Commun 9:3196
Liu, Huafeng; Li, Xin; Hu, Li et al. (2018) A crucial role of the PD-1H coinhibitory receptor in suppressing experimental asthma. Cell Mol Immunol 15:838-845
Altwerger, Gary; Bonazzoli, Elena; Bellone, Stefania et al. (2018) In Vitro and In Vivo Activity of IMGN853, an Antibody-Drug Conjugate Targeting Folate Receptor Alpha Linked to DM4, in Biologically Aggressive Endometrial Cancers. Mol Cancer Ther 17:1003-1011
Sanmamed, Miguel F; Chen, Lieping (2018) A Paradigm Shift in Cancer Immunotherapy: From Enhancement to Normalization. Cell 175:313-326
Gupta, Swati; Mani, Navin R; Carvajal-Hausdorf, Daniel E et al. (2018) Macrodissection prior to closed system RT-qPCR is not necessary for estrogen receptor and HER2 concordance with IHC/FISH in breast cancer. Lab Invest 98:1076-1083

Showing the most recent 10 out of 675 publications